WO2001069253A3 - 3d model of an fc epsilon receptor alpha chain-ige fc region complex - Google Patents

3d model of an fc epsilon receptor alpha chain-ige fc region complex Download PDF

Info

Publication number
WO2001069253A3
WO2001069253A3 PCT/US2001/008588 US0108588W WO0169253A3 WO 2001069253 A3 WO2001069253 A3 WO 2001069253A3 US 0108588 W US0108588 W US 0108588W WO 0169253 A3 WO0169253 A3 WO 0169253A3
Authority
WO
WIPO (PCT)
Prior art keywords
muteins
present
model
antibody
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/008588
Other languages
French (fr)
Other versions
WO2001069253A2 (en
Inventor
Theodore S Jardetzky
Scott Clayton Garman
Beth A Wurzburg
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heska Corp
Northwestern University
Original Assignee
Heska Corp
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heska Corp, Northwestern University filed Critical Heska Corp
Priority to AU2001245835A priority Critical patent/AU2001245835A1/en
Priority to EP01918797A priority patent/EP1305339A2/en
Priority to CA002403739A priority patent/CA2403739A1/en
Publication of WO2001069253A2 publication Critical patent/WO2001069253A2/en
Anticipated expiration legal-status Critical
Publication of WO2001069253A3 publication Critical patent/WO2001069253A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention includes three-dimensional models of complexes between antibody receptor proteins, such as FcεRIα proteins, and antibodies, such as Fc-Cε3/Cε4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stability and/or antibody binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune response.
PCT/US2001/008588 2000-03-15 2001-03-14 3d model of an fc epsilon receptor alpha chain-ige fc region complex Ceased WO2001069253A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001245835A AU2001245835A1 (en) 2000-03-15 2001-03-14 Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof
EP01918797A EP1305339A2 (en) 2000-03-15 2001-03-14 3d model of an fc epsilon receptor alpha chain-ige fc region complex
CA002403739A CA2403739A1 (en) 2000-03-15 2001-03-14 Three-dimensional model of a complex between a fc epsilon receptor alpha chain and a fc region of an ige antibody and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18985300P 2000-03-15 2000-03-15
US60/189,853 2000-03-15

Publications (2)

Publication Number Publication Date
WO2001069253A2 WO2001069253A2 (en) 2001-09-20
WO2001069253A3 true WO2001069253A3 (en) 2003-02-27

Family

ID=22699027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008588 Ceased WO2001069253A2 (en) 2000-03-15 2001-03-14 3d model of an fc epsilon receptor alpha chain-ige fc region complex

Country Status (5)

Country Link
US (2) US20030003502A1 (en)
EP (1) EP1305339A2 (en)
AU (1) AU2001245835A1 (en)
CA (1) CA2403739A1 (en)
WO (1) WO2001069253A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015716A2 (en) 2001-08-13 2003-02-27 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
EP2904093B1 (en) * 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
CN105026430B (en) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102049990B1 (en) 2013-03-28 2019-12-03 삼성전자주식회사 Fusion protein comprising anti-c-Met antibody and VEGF binding fragment
CA3244731A1 (en) 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
EP3359576B1 (en) 2015-10-08 2024-12-25 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068861A2 (en) * 2000-03-15 2001-09-20 Northwestern University THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180805A (en) * 1986-07-02 1993-01-19 Research Corporation Limited Polypeptide competitor for immunoglobulin E
US5693758A (en) * 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
US5639660A (en) * 1988-02-24 1997-06-17 Hoffmann-La Roche Inc. Polypeptide and DNA sequence corresponding to the human receptor with high affinity for IgE
AU2195395A (en) * 1994-03-28 1995-10-17 United Biomedical Inc. Synthetic peptide based immunogens for the treatment of allergy
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
US6395875B1 (en) * 1999-01-25 2002-05-28 Brookhaven Science Associates Llc Recombinant soluble adenovirus receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068861A2 (en) * 2000-03-15 2001-09-20 Northwestern University THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GARMAN E A: "Crystal structure of the human high affinity IgE receptor", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 95, 23 December 1998 (1998-12-23), pages 951 - 961, XP002136437, ISSN: 0092-8674 *
GARMAN S C ET AL: "STRUCTURE OF THE FC FRAGMENT OF HUMAN IGE BOUND TO ITS HIGH-AFFINITY RECEPTOR FCERLALPHA", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 406, no. 6793, 20 July 2000 (2000-07-20), pages 259 - 266, XP001026266, ISSN: 0028-0836 *
KEOWN M B ET AL: "BASIS OF THE 1:1 STOICIOMETRY OF THE HIGH AFFINTY RECEPTOR FC RI-IGE COMPLEX", EUROPEAN BIOPHYSICS JOURNAL, SPRINGER, TOKYO, JP, vol. 25, no. 5/6, 1997, pages 471 - 476, XP000905143, ISSN: 0175-7571 *
KOCHAN J P ET AL: "Characterization of the human IgE Fc-Fc epsilon RI alpha interaction.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. UNITED STATES 1994, vol. 347, 1994, pages 31 - 38, XP008009668, ISSN: 0065-2598 *
LETOURNEUR ODILE ET AL: "Glycosylation of human truncated Fc-epsilon-RI alpha chain is necessary for efficient folding in the endoplasmic reticulum.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 14, 1995, pages 8249 - 8256, XP002218114, ISSN: 0021-9258 *
MALISSARD MARTINE ET AL: "Recombinant soluble beta-1,4-galactosyltransferases expressed in Saccharomyces cerevisiae: Purification, characterization and comparison with human enzyme.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 239, no. 2, 1996, pages 340 - 348, XP008009711, ISSN: 0014-2956 *
See also references of EP1305339A2 *

Also Published As

Publication number Publication date
US20030003502A1 (en) 2003-01-02
WO2001069253A2 (en) 2001-09-20
CA2403739A1 (en) 2001-09-20
AU2001245835A1 (en) 2001-09-24
EP1305339A2 (en) 2003-05-02
US20060036420A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2001069507A3 (en) Proteomics database
AT500379B8 (en) TAU PROTEINS
BG104149A (en) INTERLevkin-18 Binding Proteins, Their Preparation and Administration
WO2002044426A3 (en) Nod2 nucleic acids and proteins
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
ATE352559T1 (en) METHOD FOR REDUCING THE IMMUNOGENICITY OF PROTEINS
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
EA200400312A1 (en) ANTAGONISTIC ANTIBODIES AGAINST HTNFSF13b MAN
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
DE69841110D1 (en) EXTENDED CDNS THAT CODE FOR SECRETED PROTEINS
DE69940545D1 (en) VACCINES CONTAINING ANTIIDIOTYPIC ANTIBODIES CARING FOR THE CARBOHYDRATES OF STREPTOCOCCUS GROUP B
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2004066958A3 (en) Caspase-9:bir3 domain of xiap complexes and methods of use
WO2002077186A3 (en) Human secreted proteins
EP1499353A4 (en) ANTIBODIES SPECIFICALLY BINDING TO TL5
WO2001068861A3 (en) THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF
WO2001069253A3 (en) 3d model of an fc epsilon receptor alpha chain-ige fc region complex
TW272197B (en)
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
EP0770681A3 (en) T cell epitopes of the major allergens from ambrosia artemisiifolia
ATE175209T1 (en) ALLERGIC PROTEINS FROM AMBROSIA AND USE THEREOF
WO2002026930A3 (en) Nucleic acids, proteins, and antibodies
WO2000026246A9 (en) Crystallized form of fc epsilon receptor alpha chain, its 3-d model and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2403739

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001245835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001918797

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001918797

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001918797

Country of ref document: EP